Tarveda Therapeutics has gained $30 million in funding for Pentarin second phase clinical trials through new investor, Versant Ventures. The funding will enable the pharmaceutical company to continue developing the newest cancer treatment which combines tumor targeting with reduced drug sizing, allowing them to penetrate more deeply into cancers.  Testing data is expected to be available sometime this year.